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Abstract
Summary Previous studies evaluated the association be-
tween proton pump inhibitor (PPI) use and subsequent
fracture risk, but they showed ambiguous results. Therefore,
the objective was to evaluate this association in a different
study population. Our findings show that there is probably
no causal relationship between PPI use and hip fracture risk.
Introduction Previous studies evaluated the association
between PPI use and subsequent fracture risk, but they
showed ambiguous results. To further test these conflicting
results, the objective of this study was to evaluate the
association between the use of PPIs and the risk of hip/
femur fracture in a different study population.
Methods A case-control study was conducted using data
from the Dutch PHARMO record linkage system. The
study population included 6,763 cases aged 18 years and
older with a first hip/femur fracture during enrolment and
26,341 age-, gender- and region-matched controls.
Results Current users of PPIs had an increased risk of hip/
femur fracture yielding an adjusted odds ratio (AOR) of
1.20 (95% CI 1.04–1.40). Fracture risk attenuated with
increasing durations of use, resulting in AORs of 1.26 (95%
CI 0.94–1.68) in the first 3 months, 1.31 (95% CI 0.97–
1.75) between 3 and 12 months, 1.18 (95% CI 0.92–1.52)
between 13 and 36 months and 1.09 (95% CI 0.81–1.47)
for use longer than 36 months.
Conclusion Our findings show that there is probably no
causal relationship between PPI use and hip fracture risk.
The observed association may be the result of unmeasured
distortions: although current use of PPIs was associated
with a 1.2-fold increased risk of hip/femur fracture, the
positive association was attenuated with longer durations of
continuous use. Our findings do not support that discon-
tinuation of PPIs decreases risk of hip fracture in elderly
patients.
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Introduction
Proton pump inhibitors (PPIs) are widely used to treat
several gastrointestinal disorders, including peptic ulcer
disease and gastroesophageal reflux [1]. It has been
reported that use of PPIs decreases calcium absorption in
the stomach [2, 3], which increases the risk for hip fracture
[4]. Conversely, PPIs may also reduce bone resorption
through proton pump inhibition of osteoclastic cells [5–7],
which may decrease the risk for a hip fracture.
To further investigate the clinical importance of these
opposing effects, three large epidemiological studies have
been conducted, using data from the UK General Practice
Research Database (GPRD), the databases of the Danish
national healthcare System and the Canadian Population
Health Research Data Repository. All three studies found a
positive association between the use of PPIs and risk of hip
fracture [8–10]. In addition, the UK and the Canadian study
reported that the risk of fracture further increased with
longer cumulative durations of use [8, 10]. Intriguingly,
using data from the same GPRD, two other groups of
researchers have reported different findings, which did not
support a causal relationship between PPI use and fracture
risk. In both GPRD studies, the risk of hip fracture
decreased with prolonged PPI use [11, 12].
The discrepancies between the different “duration of
use” analyses in the studies mentioned above are important,
because “duration of use” analyses provide indirect evi-
dence that may support a causal effect. Therefore, the
objective of this study was to evaluate the association
between the (duration of) use of PPIs and the risk of hip/
femur fracture in a different study population.
Methods
Study design
The Dutch PHARMO Record Linkage System (RLS) was
used to conduct a case-control study. PHARMO RLS
(http://www.pharmo.nl) includes the virtually complete
pharmacy dispensing histories of community-dwelling
residents in the Netherlands, which are linked to hospital
admission records. Pharmacy data include information
about the drug dispensed, the date of dispensing, the
prescriber, the amount dispensed, the prescribed dosage
regimen and the estimated duration of use. Hospital
discharge records include detailed information on date of
admission, discharge diagnoses and procedures. The ver-
sion of the database used for this study, represents about
7% of the general Dutch population. Patients are included
irrespective of their health insurance or socio-economic
status. Moreover, validation studies have shown that the
PHARMO RLS has a high level of data completeness and
validity [13], especially with regards to recording of hip
fractures [14, 15].
A case-control analysis was conducted within PHARMO
RLS between January 1, 1991 and December 31, 2002.
Cases were 18 years or older and sustained a hip or femur
fracture during the study period. The first hospital
admission date for a hip/femur fracture defined the index
date. The ICD codes 820–8 2 1w e r eu s e dt oi d e n t i f yh i p /
femur fractures. Up to four control patients were matched
to each case by year of birth, gender and geographical
region. The selected control patients were PHARMO RLS
participants without any fracture during enrolment. Con-
trols were assigned the same index date as their matched
case.
Exposure assessment
Current users of PPIs or histamine H2-receptor antagonists
(H2RAs) were defined as patients who had received at least
one PPI or H2RA dispensing within the 30 days before the
index date. Recent, past and distant past users received their
last dispensing in respectively the 31–91 days, 92–365 days
or >1 year before the index date.
For each current user, we calculated the average daily
dose by division of the cumulative dose by the treatment
time, using defined daily dosages (DDD) [16]. One DDD is
equivalent to 20 mg orally administered omeprazole, 40 mg
pantoprazole, 30 mg lansoprazole, 20 mg rabeprazole,
30 mg esomeprazole, 800 mg cimetidine, 300 mg raniti-
dine, 300 mg nizatidine, 150 mg roxatidine and 40 mg
famotidine. The expected continuous duration of PPI or
H2RA use was based on the prescribed drug supply and
prescribed daily dose. In case of overlap between two
dispensings (i.e. a repeat dispensing filled within the
duration of use for a previous dispensing), or a repeat
dispensing filled within 182 days after discontinuation of
the previous period, this period was then extended. In case
of missing data on daily dose, the median expected duration
of use for the PPI or H2RA of interest, was used. Because
acid suppressants may be prescribed for the treatment of
gastrointestinal side effects of oral glucocorticoids, the
main analysis was stratified to concomitant use of oral
glucocorticoids (i.e. a prescription in the 6 months before
the index date).
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hypnotics within 3 months before, and antacids other than
PPIs or H2RAs, hormone replacement therapy, beta-
blockers, antidiabetics, antipsychotics, antidepressants, anti-
convulsants, two ore more non-steroidal anti-inflammatory
drug dispensings, disease-modifying antirheumatic drugs,
average daily dose of oral corticosteroids in the 6 months
before the index date. Furthermore, we adjusted our
analyses for a history of diseases of the oesophagus/
stomach/duodenum, diabetes mellitus, rheumatoid arthritis,
inflammatory bowel disease, anaemia, mental disorders,
endocrine disorders, congestive heart failure, cerebrovascu-
lar disease and chronic obstructive pulmonary disease.
Sensitivity analyses
Two sensitivity analyses were conducted. In the first
sensitivity analysis, we restricted cases and controls to
those who had at least 1 year of follow-up time before the
index date. In the second sensitivity analysis, we did not
restrict our analyses to current PPI use only: in contrast to
the studies performed by Targownik et al. [10], de Vries et
al. [11] and the current PHARMO study, Yang et al. [8] did
not take into account the timing of PPI exposure. For
example, in his study, patients who had stopped taking PPIs
10 years before the index date were considered to have the
same increased risk of hip fracture as patients who were
taking PPIs on the index date [8]. The underlying
assumption of this study design, is that PPI-induced bone
damage, is irreversible. Conversely, during the design of the
current study, we assumed that bone damage caused by PPI
intake probably is reversible, similar to detrimental effects
on bone caused by other drugs, such as oral corticosteroids
[17, 18]. When reversibility of a side effect of a drug is
assumed, the analyses should take into account the timing
of exposure, which has been done in all our main analyses.
Statistical analysis
We used conditional logistic regression (SAS version 9.1.3,
PHREG procedure; SAS Inc., Cary, NC, USA) to quantify
the strength of the association between use of PPIs and
H2RAs and risk of hip/femur fracture. Adjusted odds ratios
(AORs) for hip/femur fracture were estimated by comparing
PPI or H2RA use with no use. The analyses were stratified
by class (PPI or H2RA), sex, continuous duration of use,
average daily dose and concomitant use of oral cortico-
steroids. Backward elimination was used to establish the
final model of confounders from the pivotal exposure
analysis. In addition, smoothing spline regression plots were
used to visualise the association between risk of hip/femur
fracture and both timing and continuous duration of use [19].
Results
We identified 6,763 patients who sustained a hip/femur
fracture and 26,341 controls (Table 1). Their mean age and
gender were equally distributed among cases and controls.
The average time period of prescribing data before the
index date was 4.1 years.
Table 2 shows that current use of both PPIs and H2RAs
was significantly associated with an increased risk of hip/
femur fracture, yielding AORs of 1.20 (95% CI 1.04–1.40)
Table 1 Baseline characteristics of cases and controls
Characteristic Cases Controls Crude
n=6,763 % n=26,341 % OR (95% CI)
Mean age (years) 75.7 75.3
Number of females 4,929 73 19,138 73
Use 6 months before the index date
Proton pump inhibitors 573 8 1,714 7 1.35 (1.22–1.49)
Histamine H2-receptor antagonists 433 6 1,412 5 1.21 (1.08–1.35)
Other antacids 204 3 576 2 1.41 (1.20–1.66)
Oral glucocorticoids 366 5 918 3 1.59 (1.40–1.80)
Disease modifying antirheumatic drugs 115 2 202 1 2.27 (1.80–2.86)
Two or more non-steroidal anti-inflammatory drug dispensings 929 14 2584 10 1.46 (1.35–1.59)
Hospitalisation before index date
Diseases of the oesophagus, stomach and duodenum 118 2 248 1 1.86 (1.49–2.32)
Cardiovascular disease 359 5 1,289 5 1.10 (0.98–1.25)
Cerebrovascular disease 296 4 565 2 2.12 (1.84–2.45)
OR odds ratio, CI confidence interval
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ing the use of acid suppressants for 1–3 months, a rapid drop
towards baseline was observed for both PPIs and H2RAs.
The risk of hip/femur fracture was statistically significantly
higher among current users of PPIs and H2RAs compared to
recent users. This association is also presented in Fig. 1.
Table 2 also shows that longer durations of use
attenuated the risk association. Current PPI users were at
highest risk during the first year of continuous exposure,
but this risk decreased over time. In addition, no increased
risk of hip/femur fracture was observed among current
users (8 cases and 29 exposed controls) with a duration of
PPI use exceeding 7 years, yielding an AOR of 0.89 (95%
CI 0.34–2.01). The association between the duration of
continuous PPI and H2RA use, and the risk of hip fracture
is graphically illustrated in Fig. 2.
Furthermore, the risk of hip/femur fracture was highest
among those current users who received the highest daily
dose of PPIs. The PPI use below an average daily dose of
1.00 DDD, resulted in an AOR of 1.21 (95% CI 0.93–1.57)
as shown in Table 3. This risk declined to an AOR of 1.12
(95% CI 0.88–1.42) among users receiving a DDD between
1.00 and 1.75, but extended to a statistically significant
increased risk among those who received more than 1.75
DDD, yielding an AOR of 1.35 (95% CI 1.02–1.77). After
comparing the results for average daily dose of PPIs with
the average daily dose of H2RAs, no statistically significant
differences were observed between both groups.
Table 4 shows the risk of hip fracture among current PPI
users when stratifying according to concomitant use of oral
glucocorticoids. Exposure to oral glucocorticoids increased
fracture risk, while those who received 15 mg prednisolone
Table 2 Use of PPIs or H2RAs and risk of hip fracture, by duration of use
Cases (n=6,763) % Controls (n=26,341) % Crude OR (95% CI) Adjusted
a OR (95% CI)
PPI use before
Never 5,810 85.9 23,430 88.9 1.00 1.00
Distant past use 305 4.5 907 3.4 1.38 (1.21–1.58) 1.24 (1.08–1.43)
Past use 75 1.1 290 1.1 1.08 (0.83–1.39) 0.97 (0.74–1.26)
Recent use 268 4.0 941 3.6 1.18 (1.03–1.36) 0.96 (0.83–1.12)
Current use 305 4.5 773 2.9 1.62 (1.41–1.86)
b 1.20 (1.04–1.40)
b
Duration of use
c
≤3 months 71 1.0 177 0.7 1.63 (1.24–2.15) 1.26 (0.94–1.68)
4–12 months 72 1.1 165 0.6 1.79 (1.36–2.38) 1.31 (0.97–1.75)
13–36 months 94 1.4 251 1.0 1.55 (1.22–1.97) 1.18 (0.92–1.52)
>36 months 68 1.0 180 0.7 1.54 (1.16–2.05) 1.09 (0.81–1.47)
H2RA use before
Never 5,624 83.2 22,545 85.6 1.00 1.00
Distant past use 598 8.8 2,020 7.7 1.18 (1.07–1.30) 1.01 (0.90–1.12)
Past use 108 1.6 364 1.4 1.21 (0.97–1.50) 1.03 (0.83–1.29)
Recent use 237 3.5 892 3.4 1.06 (0.92–1.23) 0.91 (0.78–1.06)
Current use 196 2.9 520 2.0 1.52 (1.28–1.80)
d,e 1.19 (1.00–1.42)
d
Duration of use
c
≤3 months 47 0.7 104 0.4 1.85 (1.30–2.62) 1.57 (1.10–2.24)
4–12 months 43 0.6 116 0.4 1.51 (1.06–2.15) 1.14 (0.79–1.64)
13–36 months 51 0.8 168 0.6 1.22 (0.89–1.68) 0.92 (0.67–1.28)
>36 months 55 0.8 132 0.5 1.64 (1.19–2.25) 1.30 (0.94–1.81)
OR odds ratio, CI confidence interval
aAdjusted for use of other antacids, average daily dose of oral corticosteroids, anxiolytics/hypnotics, short- or long-acting benzodiazepines, hormone
replacement therapy, anticonvulsants, antipsychotics, antidepressants, beta-blockers, antidiabetics, two ore more non-steroidal anti-inflammatory drug
dispensings, disease modifying antirheumatic drugs, a history of digestive system disorders, anaemia, mental disorders, cerebrovascular disease, congestive
heart failure, endocrine disorders, rheumatoid arthritis, diabetes mellitus, chronic obstructive pulmonary disease and inflammatory bowel disease.
Furthermore, the proton pump inhibitor (PPI) analysis was adjusted for the use of histamine H2-receptor antagonists (H2RAs) and the H2RA analysis for
the use of PPIs
bWald statistic: current PPI use statistically significantly different (P<0.05) from recent PPI use
cDuration of use: duration of continuous use with washout periods of ≤3 months
dWald statistic: current H2RA use statistically significantly different (P<0.05) from recent H2RA use
eWald statistic: current H2RA use statistically significantly different (P<0.05) from distant H2RA use
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[95% CI 1.07–5.20]).
Stratification according to sex showed that risk of
fracture was statistically significantly higher among current
PPI users who were men, AOR 1.57 (95% CI 1.16–2.12),
compared to women AOR 1.12 (95% CI 0.94–1.32) with a
P value <0.05. Although not statistically significant, we
observed the same trend among current H2RA users.
In the first sensitivity analysis, we restricted cases and
controls to those who had at least 1 year of follow-up time
before the index date. Current users of PPIs or H2RAs had
the following risks of hip/femur fracture: AORs 1.25 (95%
CI 1.07–1.47) for PPI users and 1.12 (95% CI 0.92–1.35)
for H2RAs users. This was not different from the findings
in Table 2.
In the second sensitivity analysis, we lumped current,
recent and past PPI use categories, and stratified them by
cumulative duration of use, similar to the methodology of
Yang et al. [8]. There was still an inverse relationship
between duration of PPI use and hip fracture, with a slightly
decreased magnitude: AORs were 1.13 (95% CI 1.02–1.25)
for patients using PPIs up to 1 year, 1.21 (95% CI 0.98–
1.50) for 1–2 years, 1.03 (95% CI 0.78–1.35) for 2–3 years
and 0.96 (95% CI 0.78–1.20) for PPI exposure exceeding
3 years. There was no association between H2RA users and
hip fracture (data not shown).
Discussion
We found that current PPI use was associated with a 1.2-
fold increased risk of hip/femur fracture. Higher daily
dosages (>1.75 DDD), male gender, and use of oral
corticosteroids further increased the risk. The highest
increase of risk was observed within the year after initiation
of acid suppressants, and attenuated with prolonged use.
This finding, does not support a causal effect of PPIs on
bone, but suggests the presence of unmeasured distortion,
such as selection bias and/or residual confounding.
The key finding of this study is that the increased risk of hip/
femurfractureamongcurrentacidsuppressantusersisprobably
not causal. As far as we know, PPIs and H2RAs do not increase
the risk of falling. Therefore, if a causal relationship exists,
fracture risk should increase only after long-term exposure (at
least 6–12 months to alter bone mineral density). However, the
smoothing spline regression plots (Fig. 2) did not provide
evidence for a duration of use effect. Furthermore, acid
suppression in the stomach caused by PPIs is significant
greater and lasts longer compared with H2RAs [1, 20]. Thus,
if impaired calcium absorptionc a u s e db ya c i ds u p p r e s s i o ni s
associated with an increased risk of fracture, this should be
most abundant with PPI use. Nevertheless, prolonged H2RA
use (instead of PPI use) of >36 months yielded a higher AOR
of 1.30 (95% CI 0.94–1.81) compared to PPI use with an
AOR of 1.09 (95% CI 0.81–1.47). These results support the
alternative hypothesis that the observed association is flawed
due to unknown distortion, instead of an increased fracture
risk caused by impaired calcium absorption. Consequently,
these results do not support the hypothesis that acid
suppression is associated with an increased risk of fracture.
Clinical studies showed conflicting results regarding
calcium uptake and osteoclastic pump inhibition in users
of PPIs [21]. When studying calcium uptake along with a
meal, Graziani et al. and Hardy et al. [3, 22] found that
calcium uptake was decreased in hypochlorhydric subjects,
whereas other studies did not observe any effect [23–25].
Only during fasting conditions calcium uptake was de-
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achlorhydric patients [23, 26]. Furthermore, some in vitro
[6, 7] and in vivo [5] studies suggested that PPIs could
inhibit the osteoclastic proton pump and thereby reduce
bone resorption. Conversely, short-term omeprazole treat-
ment did not alter osteoclast or osteoblast function in
paediatric users [27]. Moreover, no significant differences
were observed in BMD among postmenopausal women
using acid suppressants (PPIs and H2RA), while in men,
even lower cross-sectional bone masses were observed
[28]. In addition, the most recent study performed by
Targownik et al. [29] showed that both chronic PPI use and
high daily doses of PPIs were not associated with
osteoporosis or accelerated BMD loss.
Several observational studies that investigated the
association between duration of acid suppressant use and
fracture risk found discrepant results as well [8, 10–12].
Both Yang et al. and Targownik et al. [8, 10] found that
fracture risk increased with longer durations of PPI use. In
contrast, members of our group found results which are
Table 4 Use of PPIs or H2RAs and risk of hip fracture, by exposure to oral corticosteroids
Cases (n=6,763) % Controls (n=26,341) % Crude OR (95% CI) Adjusted
a OR (95% CI)
PPI use before
Never 5,810 85.9 23,430 88.9 1.00 1.00
Current use 305 4.5 773 2.9 1.62 (1.41–1.86) 1.20 (1.04–1.40)
By oral corticosteroid use in the 6 months before
b
Unexposed 256 3.8 682 2.6 1.54 (1.33–1.79)
c 1.19 (1.02–1.40)
<7.5 mg/day 21 0.3 47 0.2 1.86 (1.11–3.12) 1.31 (0.77–2.22)
7.5–15 mg/day 12 0.2 20 0.1 2.51 (1.21–5.18) 1.91 (0.90–4.07)
≥15 mg/day 13 0.2 14 0.1 3.67 (1.72–7.84)
c 2.35 (1.07–5.20)
H2RA use before
Never 5,624 83.2 22,545 85.6 1.00 1.00
Current use 196 2.9 520 2.0 1.52 (1.28–1.80) 1.19 (1.00–1.42)
By oral corticosteroid use in the 6 months before
b
Unexposed 165 2.4 468 1.8 1.42 (1.19–1.71) 1.18 (0.98–1.43)
<7.5 mg/day 16 0.2 24 0.1 2.64 (1.39–4.99) 1.73 (0.90–3.35)
7.5–15 mg/day 9 0.1 16 0.1 2.29 (1.01–5.19) 1.43 (0.61–3.38)
≥15 mg/day 5 0.1 6 0.0 3.59 (1.09–11.78) 2.34 (0.68–8.06)
OR odds ratio, CI confidence interval
aAdjusted for same confounders listed in Table 2
cCorticosteroids by prednisolone equivalents; data not shown for patients with only 1 oral steroid dispensing before the index date
dWald statistic: the risk of hip fracture is statistically significantly higher among PPI users exposed to corticosteroids ≥15 mg/day compared with PPI users
unexposed to corticosteroids (P<0.05)
Table 3 Use of PPIs or H2RAs and risk of hip fracture, by daily dose
Use before PPI H2RA
Adjusted
a OR (95% CI) Adjusted
a OR (95% CI)
Never 1.00 1.00
Current use 1.20 (1.04–1.40) 1.19 (1.00–1.42)
Average daily dose, DDD
First time user 1.29 (0.79–2.09) 1.40 (0.78–2.51)
<1.00 1.21 (0.93–1.57) 0.93 (0.73–1.18)
b
1.00–1.75 1.12 (0.88–1.42) 1.67 (1.21–2.31)
b
>1.75 1.35 (1.02–1.77) 1.57 (0.89–2.77)
OR odds ratio, CI confidence interval, DDD defined daily dosage
aAdjusted for the same confounders listed in Table 2
bWald statistic: the risk of hip fracture is statistically significantly lower among current H2RA users with <1.00 DDD compared with current H2RA users
with 1.00–1.75 DDD (P<0.05)
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≤1 year is associated with the highest fracture risk) using
the same database as Yang et al. [11]. Moreover, our
sensitivity analysis, in which we resembled the definitions
of Yang et al., did not support a duration-of-use effect.
Additionally, Kaye et al. [12] who also used the GPRD
database did not find any association between the number
of PPI prescriptions and hip fracture. The reasons for these
discrepancies remain unclear.
There are alternative explanations for the small, overall
1.2-fold increased risk among current users of acid
suppressants. These include the inability of the current
and previous studies, to measure (or only partially measure)
alcohol consumption, smoking history and low body mass
index. All these factors are associated with an increased risk
of fracture [30–32]. Besides, PPIs are often used for the
eradication of Helicobacter pylori [33], which may be
associated with an increased risk of osteoporosis [34]. In
addition, PPIs are associated with the onset of Clostridium
difficile [35], which may be an alternative explanation for
the increased risk of fracture. Finally, celiac disease, which
is associated with the onset of reflux oesophagitis [36], has
recently been associated with an increased risk of both
osteoporosis and fracture [37]. Nevertheless, we were
unable to fully adjust for these three potential confounders,
because PHARMO RLS has missing data of diagnoses
determined outside the hospital.
Our study has several strengths. As we used a
population-based design, our study represents the entire
population of the Netherlands. It has a large study size and
the average period of follow-up exceeded 4 years. Further-
more, written dosage instructions allowed us to discrimi-
nate between different average daily doses of PPIs and
H2RAs and concomitant use of average daily dosages of
oral glucocorticoids. The main limitation of our study is the
inability to adjust for residual confounding. No information
was present in the PHARMO RLS about low body mass
index, alcohol consumption, smoking, celiac disease, C.
difficile and H. pylori eradication. These potential con-
founders could have overestimated the observed increased
fracture risk. Conversely, no information was present about
the use of over-the-counter drugs like calcium and vitamin
D supplements, which decrease this risk [4, 38]. Yet,
according to our knowledge, the trend observed in the
spline showing the recency of use (Fig. 1) would be similar,
even after adjustments for these potential confounders. In
addition, although not confirmed by clinical trials, current
literature suggests that non-steroidal anti-inflammatory
drugs inhibit bone formation [39]. For this reason, our
analyses were adjusted for the use of these drugs in the
6 months before the index date. Finally, data collection for
this study ended on the 31st of December 2002. Addition of
more recent data would probably identify more long-term
PPI users, which would add more power to the duration of
use results.
In conclusion, our findings show that there is probably
no causal relationship between PPI use and hip fracture
risk. The observed association may be the result of
unmeasured distortions: although current use of PPIs was
associated with a 1.2-fold increased risk of hip/femur
fracture, the positive association was attenuated with longer
durations of continuous use. Our findings do not support
that discontinuation of PPIs decreases risk of hip fracture in
elderly patients.
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